Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Contacts

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq:RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two upcoming investor conferences. Details for the presentations are as follows.

TD Cowen 44th Annual Healthcare Conference


Panel Discussion: Gynecological Cancers


Date: Tuesday, March 5, 2024


Time: 10:30 a.m. Eastern Time


Location: Boston, MA

Bloom Burton 2024 Healthcare Investor Conference


Company Overview


Date: Tuesday, April 16, 2024


Time: 3:30 p.m. Eastern Time


Location: Toronto, ON

A live webcast of the TD Cowen corporate panel discussion and Bloom Burton company overview can be accessed in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company’s website for at least 30 days.

About Repare Therapeutics, Inc.


Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1/2 clinical development; camonsertib (also known as RP-3500), a potential leading ATR inhibitor currently in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical Polθ ATPase inhibitor program; as well as additional, undisclosed preclinical programs. For more information, please visit reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.

SNIPRx® is a registered trademark of Repare Therapeutics Inc.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.